SBIR/STTR Research Award

A novel biodegradable nerve conduit drug delivery device for peripheral nerverepair

Award identifier 8a1ee2b5a1681c9e2fe64dc2a1b8a8ae191852a1f633af895b76934a8df393c1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

STTR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Microsurgical Innovations Inc
Proposal award date
2019-09-30
Contract end date
2020-08-31
UEI
MHRBUTN4H3B7
Solicitation number
PA18-574
Topic code
999

Research abstract

Project Summary Nerve injury can occur due to traumachronic compression or disease processes such as diabetes or tumors and have a tremendous socioeconomic impact from loss of work and healthcare costsThere is still a clinical need to improve recovery from nerve injuriesand a new nerve conduit drug delivery device that addresses this clinical need is the focus of the present proposalOur group has developed a patented drug delivering conduit for use in peripheral nerve surgery that can release growth factors and or small molecules in a controlled manner to the regenerating nerve and can be used in a variety of peripheral nerve injury or repair applicationsBy taking advantage of the simple physical process of diffusion we have designed a hole based drug delivery system that demonstrates controlled releaseIn this proposal we plan to use our unique nerve conduit device to locally deliver a neurotrophic small moleculeFKThe overall objective is to demonstrate that our patented nerve conduitthat locally releases FKcan enhance functional recovery when used ito bridge a nerve gap and iiin conjunction with autologous nerve graft repair of a peripheral nerve injury in a rat sciatic nerve modelIn Aima we will utilize rapid prototyping to manufacture a device that can release FKfordays at a concentrationng mLthat has been shown to be neurotrophicWe will evaluate the FKrelease kinetics over the release period using a commercially available ELISAWe will then evaluateAimbthe efficacy of our nerve guide drug delivery device to improve functional outcomesas measured by sciatic functional index and muscle atrophyin two different rat sciatic nerve surgical repair strategiesto bridge a nerve gap andin conjunction with autologous nerve graft repairWe will evaluate the primary outcome variablessciatic functional index and muscle atrophyand secondary measures including nerve histomorphometryneuromuscular junction connectivityand electrophysiology atdays post surgeryWe expect to see greater improvements in functional recovery when the sciatic nerve injury is repaired with the combination of standard surgical repair AND local FKdelivery compared to standard repair aloneWe have set to two primarygono gomilestones to provide sufficient evidence for continuation of the commercialization plan and warrant Phase II fundingOur FKreleasing device will result in statistically greater improvements in functional recoverygait and muscle massthan an FDA approved device and equivalent to an autograft in bridging acm nerve gap andOur FKdevice combined with an autograft will have statistically better functional outcomes than treatment of acm gap injury with autograft aloneThis approach of locally releasing FKfrom our novel drug delivering conduit could potentially transform current nerve repair strategies and dramatically improve the functional outcomes following peripheral nerve repair Project Narrative Peripheral nerve injuries such as those that occur with traumafracturesor nerve plexus injuries are particularly devastating and often have few treatment optionsmost of which result in long term disabilitiesOur approach of locally releasing neurotrophic drugs from a novel drug delivering conduit could potentially transform current nerve repair strategies and dramatically improve the functional outcomes following peripheral nerve repair

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2016–2025). Reported award amounts total $2,757,354. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.